FY 2019 REVENUES
REVENUES GROWTH IN FY 2019
ONCOLOGY ORDERS GROWTH IN FY 2019
NON-GAAP EPS 1 GROWTH IN FY 2019
Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance for its Ethos™ therapy, an Adaptive Intelligence™ solution. Ethos therapy is an artificial intelligence (AI)-driven...
Varian (NYSE: VAR) today announced it has signed an agreement with Massachusetts General Hospital to provide seven Varian radiotherapy systems and related services for advanced cancer treatment at...
First Quarter 2020 Summary Oncology Systems gross orders grew 8% in dollars or 9% in constant currency in the quarter and over the trailing twelve months Total company revenues grew 12% in...
Varian (NYSE: VAR) today announced it has appointed Dr. Ricky Sharma, to vice president of Clinical Affairs. In this role he will be leading medical research, translational science and clinical...
View all press releases
View all events
Participant Dial-In: 877-407-9708 / 201-689-8259
Teleconference: Access from within the U.S. by dialing 1-877-869-3847, and from outside the U.S. by dialing 1-201-689-8261. Replay: Access from within the U.S. by dialing 1-877-660-6853 and from...
Registration is required. Please email Katie Glenn at email@example.com by November 8, 2019.
View more events
Q1 FY20 Earnings Results
View all quarterly results
FY19 Annual Report
FY18 Sustainability Report
View all reports
VP, Treasurer and Investor Relations
1 650 424 6081
Varian Corporate Headquarters
3100 Hansen Way
Palo Alto, CA 94304-1038
Stay up to date on the latest investor information.